<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939497</url>
  </required_header>
  <id_info>
    <org_study_id>1119/07</org_study_id>
    <nct_id>NCT00939497</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions</brief_title>
  <official_title>Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
        -  To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals&#xD;
           Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical&#xD;
           Products, LP, USA, in healthy human adult subjects, under fasting conditions.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
        -  A randomized, open label, two treatment, two period, two sequence, single dose,&#xD;
           crossover study, under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy human adult subjects between 18-55 years of age (inclusive), having a body&#xD;
             mass index (BMI) between 18 and 27 kg/m2.&#xD;
&#xD;
          2. Subjects who have no evidence of underlying disease during screening history and whose&#xD;
             physical examination is performed within 21 days prior to commencement of the study.&#xD;
&#xD;
          3. Subjects whose screening laboratory values are within normal limits or considered by&#xD;
             the physician/Principal Investigator to be of no clinical significance.&#xD;
&#xD;
          4. Informed consent given in written form according to section 11.3 of the protocol.&#xD;
&#xD;
          5. Female Subjects:&#xD;
&#xD;
               -  Of child bearing potential practicing an acceptable method of birth control for&#xD;
                  the duration of the study as judged by the investigator(s), such as condoms,&#xD;
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.&#xD;
&#xD;
               -  Postmenopausal for at least 1 year.&#xD;
&#xD;
               -  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
                  hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of significant:&#xD;
&#xD;
               -  Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,&#xD;
                  endocrine, immunologic, dermatologic, musculoskeletal, neurological or&#xD;
                  psychiatric disease.&#xD;
&#xD;
               -  Alcohol dependence, alcohol abuse or drug abuse within past one year.&#xD;
&#xD;
               -  Moderate to heavy smoking (&gt;10 cigarettes/day) or consumption of tobacco&#xD;
                  products.&#xD;
&#xD;
               -  History of difficulty in swallowing tablet / capsule.&#xD;
&#xD;
               -  Clinically significant illness within 4 weeks before the start of the study&#xD;
&#xD;
               -  Asthma, urticaria or other allergic type reactions after taking any medication.&#xD;
&#xD;
               -  Positive urine drug screening, HIV, Hepatitis B &amp; C tests.&#xD;
&#xD;
               -  Any history of hypersensitivity to Risperidone.&#xD;
&#xD;
               -  Existence of any surgical or medical condition, which, in the judgment of&#xD;
                  clinical investigator might interfere with the pharmacokinetics of the drug or&#xD;
                  likely to compromise the safety of the subject.&#xD;
&#xD;
               -  Inability to communicate or co-operate with the investigator due to language&#xD;
                  problem, attitude, poor mental development / impaired cerebral function.&#xD;
&#xD;
          2. Subject who has participated in any other clinical trial involving drug administration&#xD;
             and collection of blood samples or has donated blood in the preceding 12 weeks prior&#xD;
             to the start of the study.&#xD;
&#xD;
          3. Subjects who have:&#xD;
&#xD;
               -  Systolic blood pressure less than 90 mm of Hg or more than 150 mm of Hg.&#xD;
&#xD;
               -  Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor&#xD;
                  deviations (2-4 mm Hg) at check-in may be acceptable at the discretion of the&#xD;
                  physician /investigator.&#xD;
&#xD;
               -  Pulse rate below 50/minute or above 105/minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Lotus Labs Pvt. Ltd.</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

